Russell Frank Company’s Pacira BioSciences PCRX Stock Holding History

Russell Frank Company’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$3.12M	Sell	58,965 -23,755	-29%	-$1.39M	0.01%	1613
2015 Q4	$6.37M	Buy	82,720 +74,720	+934%	+$4.23M	0.01%	1144
2015 Q3	$329K	Buy	+8,000	New	+$490K	﹤0.01%	2607
2015 Q2	–	Sell	-44,195	Closed	-$3.93M	–	3069
2015 Q1	$3.93M	Sell	44,195 -48,647	-52%	-$4.94M	0.01%	1384
2014 Q4	$8.21M	Sell	92,842 -10,069	-10%	-$952K	0.01%	988
2014 Q3	$9.97M	Sell	102,911 -19,160	-16%	-$1.86M	0.02%	900
2014 Q2	$11.2M	Buy	122,071 +7,244	+6%	+$552K	0.02%	846
2014 Q1	$8.04M	Buy	114,827 +40,868	+55%	+$2.78M	0.01%	1009
2013 Q4	$5.05M	Buy	73,959 +13,913	+23%	+$732K	0.01%	1233
2013 Q3	$2.89M	Buy	60,046 +3,729	+7%	+$136K	0.01%	1656
2013 Q2	$1.63M	Buy	+56,317	New	+$1.63M	﹤0.01%	1864

Other funds holding PCRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Russell Frank Company's PCRX Position: Q1 2016 in Review

Russell Frank Company reduced its Pacira BioSciences (PCRX) stake by 29% in Q1 2016, selling an estimated $1.39M and leaving 58,965 shares worth $3.12M. The position accounts for 0.01% of the portfolio, ranked #1613.

Russell Frank Company first reported a position in PCRX in Q2 2013 and has held it in 11 quarters since. The position peaked at $11.2M in Q2 2014. 180 funds tracked by Wall St. Rank hold PCRX as of Q1 2016.

Russell Frank Company held 58,965 shares of Pacira BioSciences worth $3.12M as of Q1 2016.
Russell Frank Company sold 23,755 Pacira BioSciences shares in Q1 2016, an estimated $1.39M.
Pacira BioSciences made up 0.01% of Russell Frank Company's portfolio in Q1 2016, its #1613 holding.
Russell Frank Company first reported a position in Pacira BioSciences in Q2 2013 and has held it in 11 quarters since.
Russell Frank Company's Pacira BioSciences position peaked at $11.2M in Q2 2014.
180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.